Internal Medicine
pejman porouhan; Reza Yousefabadi; Alaleh Abbaspour; Babak PeyroShabany; Danial Fazilat-Panah; Ahmad Foroughi; Seyed Alireza Javadinia
Abstract
Background: To investigate the survival of patients with brain metastases (BM) in Sabzevar.Materials and Methods: In this retrospective cross-sectional study at two oncologic centers in Sabzevar, patients with BM either at the presentation or at during the follow-up were enrolled. Patients' documents ...
Read More
Background: To investigate the survival of patients with brain metastases (BM) in Sabzevar.Materials and Methods: In this retrospective cross-sectional study at two oncologic centers in Sabzevar, patients with BM either at the presentation or at during the follow-up were enrolled. Patients' documents were reviewed in terms of clinical and pathological features of the primary tumor, first-line treatments and treatments at the time of BM diagnosis and finally overall survival (OS) and BM-related survival rates. The data was entered into SPSS version 26 software and analyzed at a significance level of P<0.05.Results: Eighty-four patients were enrolled (58.33% female, median age 57 [25-83]). Most frequent primary cancers were lung (non-small cell, 38.1%) and breast (34.52%). BM at the diagnosis of primary tumor was presented in 29 patients (34.5%). 61.9% had ≥5 BM, 97.6% were symptomatic, 80% had extracranial metastases (ECM). Headache (22.6%) and focal neurologic deficit (21.4%) were the most frequent reported symptoms. Primary BM treatments were: Surgery 6.1%; SRT 0%; whole brain radiotherapy (WBRT) 87.8%, systemic treatments 6.1%; best supportive care (BSC) 0%. Median OS after BM diagnosis for all was 5 months (surgery: 11, systemic: 3, WBRT: 5). In patients treated with WBRT, 64.8% had ≥5 BM, 83.3% ECM, 16.9% were ≥70 years.Conclusion: Survival of patients with BM is extremely poor. WBRT is the main treatment option. Patients who can tolerate the surgery may survive more.